Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16801 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Akimasa Sanagawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Hypertriglyceridemia, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Minophagen Pharmaceutical.
Abstract (Originalsprache)
Bexarotene is an effective oral drug for the treatment of cutaneous T‐cell lymphoma, but careful management is required due to its various side effects. In particular, hypertriglyceridemia often requires a reduction or even suspension of bexarotene therapy. The risk factors of bexarotene‐associated severe hypertriglyceridemia are not clear. Here, we conducted a post hoc analysis of the data from our previous clinical trial, which confirmed the efficacy and safety of combined bexarotene and phototherapy, to evaluate the effect of body mass index on bexarotene‐associated hypertriglyceridemia. Twenty‐five subjects were divided into two subgroups: normal and underweight (body mass index [BMI]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
- Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.
- Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
ORCID-Profile: Akimasa Sanagawa, Yoko Furukawa-Hibi, Akimichi Morita
Förderung
- Minophagen Pharmaceutical
Zitieren
APA
Sanagawa, A., Hayakawa, T., Nishida, E., Yamamoto, A., Ikumi, K., Mori, Y., Hotta, Y., Kimura, K., Furukawa-Hibi, Y., & Morita, A. (2023). Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16801
Vancouver
Sanagawa A, Hayakawa T, Nishida E, Yamamoto A, Ikumi K, Mori Y, et al. Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16801
BibTeX
@article{Sanagawa2023,
author = {Sanagawa, Akimasa and Hayakawa, Tomoaki and Nishida, Emi and Yamamoto, Aya and Ikumi, Kyoko and Mori, Yukari and Hotta, Yuji and Kimura, Kazunori and Furukawa-Hibi, Yoko and Morita, Akimichi},
title = {Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16801}
}
EUVIMED